SCHEMBL24974652

SCHEMBL24974652

CC(C)(C)OC(=O)CCS(=O)(=O)N1CCC(C2CC(=O)N(c3ccccc3)C2=O)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MT-CO2 P00403 6/20 0.42
ALOX5 P09917 6/20 0.42
GPR119 Q8TDV5 1/20 0.40
ALDH1A1 P00352 4/20 0.38
LMNA P02545 3/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 3/20 0.38
MAPT P10636 2/20 0.38
HPGD P15428 2/20 0.38
MEN1 O00255 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HSD17B10 Q99714 1/20 0.38
POLB P06746 1/20 0.37
MCL1 Q07820 1/20 0.37
USP2 O75604 1/20 0.37
HSP90AA1 P07900 1/20 0.37
HTT P42858 1/20 0.37
APOBEC3G Q9HC16 1/20 0.37
NPC1 O15118 1/20 0.37
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24974651 0.87 MT-CO2 (0.45) MT-CO2ALOX5ALDH1A1LMNAGAA
SCHEMBL21150756 0.81 GPR119 (0.37) MT-CO2ALOX5GPR119ALDH1A1LMNA
SCHEMBL21150772 0.75 ITGB3 (0.38) GPR119LMNAMAPTPOLBNPC1
SCHEMBL21151877 0.66 KMT2A (0.48) ALDH1A1LMNAKMT2AMEN1HTT
SCHEMBL21150757 0.65 ALDH1A1 (0.39) ALDH1A1KMT2AMAPTMEN1
SCHEMBL8406024 0.64 GAA (0.59) MT-CO2ALOX5ALDH1A1LMNAGAA
SCHEMBL17367673 0.63 KDM4E (0.51) ALDH1A1LMNAGAAPOLB
SCHEMBL5717433 0.62 NPSR1 (0.43) ALDH1A1MAPTHPGDNPSR1HSD17B10
SCHEMBL5220373 0.62 MAPT (0.60) ALDH1A1KMT2AMAPTHPGDNPSR1
SCHEMBL6818187 0.61 GAA (0.50) MT-CO2ALOX5ALDH1A1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572370-B2 CD16A binding agents and uses thereof BIOHAVEN THERAPEUTICS LTD. (US) 2023-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572370-B2 CD16A binding agents and uses thereof FCGR1A, FCGR2A, FCGR3B MT-CO2 4876/4885ALOX5 1220/4885GPR119 926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.